Overview

ASP8825 - Study in Patients With Restless Legs Syndrome

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To demonstrate the superiority of ASP8825 over placebo and the dose response in patients with restless legs syndrome
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc